Navigation Links
NIH funds advanced development of 3 biodefense vaccines
Date:10/7/2010

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced three new contracts to fund research on vaccines to protect against emerging infectious diseases and biological threats that could be used in a terror attack. Each project focuses on simple and efficient vaccine delivery approaches that could be deployed quickly. The total funding for the three contracts could reach $68 million, depending on the successful completion of defined project milestones.

"These new contracts build on NIAID's commitment to support the advanced development of products that are important to the public health but often unattractive to investors in private industry, by bridging the funding gap with contracts intended to address specific health needs," says NIAID Director Anthony S. Fauci, M.D.

The three studies will focus on a dengue vaccine delivered by a needle-free device, an anthrax vaccine delivered orally and an anthrax vaccine delivered in conjunction with an adjuvanta compound that stimulates the immune system.

"Our goal is to improve vaccine delivery and the resulting immune response in a way that could be used to protect large numbers of patients," said Michael G. Kurilla, M.D., Ph.D., director of the Office of Biodefense Research Affairs in NIAID's Division of Microbiology and Infectious Diseases.

The dengue vaccine is being developed by Inviragen Inc. of Fort Collins, Colo. The vaccine is tetravalent, or designed to protect against any of the four related viruses that cause dengue fever. A needle-free system, developed by PharmaJet of Golden, Colo., will be used to deliver the liquid vaccine through the skin at a high speed. Researchers anticipate that protection will be possible with one to two doses. The NIAID award will support clinical testing of the vaccine product. While tetravalent dengue vaccines previously have reached clinical trials, the manufacturing process and delivery method of this vaccine are new. Inviragen has received an initial award of $1.8 million, with the possibility of further funding of up to a total of $15.5 million over the next five years if clinical milestones are met.

PaxVax Inc. of San Diego will develop and test two formulations of an anthrax vaccine. Both formulations contain a gene known as rPA, which codes for a protein that protected animals from anthrax in previous studies. The gene will be inserted into a carrier virus or vector called adenovirus 4 and the vaccine delivered orally via a capsule. The adenovirus 4 vector is a modified live-virus vaccine that has been studied for more than 40 years and has a good safety profile in humans. Pending review and approval of the Investigational New Drug Application by the Food and Drug Administration, a Phase 1 clinical trial will be conducted to select one of the two formulations for further development. NIAID has made an initial award of $3.8 million to PaxVax. If milestones are met, the total award could amount to $23.8 million over the next nine years.

Emergent Biosolutions of Rockville, Md., also will develop and test an anthrax vaccine. The candidate vaccine consists of Emergent's licensed anthrax vaccine (BioThrax) combined with an adjuvant. The investigational vaccine was tested in a Phase 1 clinical trial prior to the award of this contract. This new award will fund manufacturing, stability studies, assay validation and clinical trial preparation of the vaccine product. After those activities are completed, the vaccine may begin Phase 2 clinical testing. Emergent has received an initial award of $9.1 million, with the potential for total funding of up to $28.7 million over the next four years if clinical milestones are met.

Clinical trials of all three vaccine products should begin within three years.

"Ultimately, the goal is to be able to use these vaccine technologies not just in response to emergencies, but worldwide in a variety of situations," said Dr. Kurilla.


'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. European partnership funds research toward robot aides for the elderly
2. The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen
3. NIH funds 10 international centers of excellence for malaria research
4. NHLBI funds research to improve safety of red blood cell transfusions
5. Why Would Anyone Attempt 200 Skydives in One Day? A Minnesota Man Will To Raise Awareness and Funds for Parkinson's Disease
6. Amazing Grace Charity Golf Tournament to Raise Awareness, Funds for Neuroblastoma
7. Only 5 percent of cancer research funds are spent on metastases, yet it kills 90 percent of all cancer patients
8. Just Graduated College Seniors Ride for Loved Ones With Diabetes Cycling Cross Country to Raise Funds to Help Find a Cure
9. Prize4Life Launches “Art, Life, Spring” Online Art Auction to Raise Funds for Lou Gehrig's Disease Research
10. Major League Baseball Players Alumni Help Lazarex Cancer Foundation Raise Funds
11. EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and Roadie, ... use or need, from clothes to couches to dressers and bicycles. Roadie — the ... to the nearest Goodwill donation center through February 28th. , “January is an ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated ... Institute. For Betsy, the clinical trial has been life-saving as she has been ... , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and ... out for each of his children. “The Angel” is the creation of published author, ... New York City, and impassioned writer. , When asked of her new book, Marjorie ...
(Date:1/20/2017)... ... ... “Christmas in Suffolk”: a story of love, secrets, and mystery. “Christmas in ... where she works in a daycare and looks for inspiration in the local coffee ... Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... 2017 Conference Call and Webcast to Follow ... it will release results for the fourth quarter of 2016 on ... ... call at 4:30 PM ET on Wednesday, February 15, 2017, during ... financial results and other corporate activities. To participate in the conference ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology: